Congestive Heart Failure Drugs Market Size Will Attain USD 20.43 BN By 2030

The Global Congestive Heart Failure Drugs Market Size accounted for USD 7.15 billion in 2022  and is estimated to achieve a market size of USD 20.43 Billion by 2030 growing at a CAGR of 15.9% from 2022 to 2030.

Request Free Sample of This Report@

Key Takeaways:

  • By Drug Class, the U.S. Congestive Heart Failure Drugs market was valued at USD 2.9 Billion in 2021 and expected to witness growth at a CAGR of 14.8% from 2022 to 2030.
  • In 2021, the ACE inhibitors segment held the largest share due to its high prescription rate and market penetration
  • By drug class, the others segment is expected to be the fastest-growing segment over the forecast period due to the launch of sodium-glucose co-transporter 2 (SGLT2) inhibitors
  • By distribution channel, the retail pharmacies segment is expected to witness lucrative growth over the forecast period due to its high compatibility with home care settings and prescription drugs
  • North America was the largest revenue-generating region in 2021. This can be attributed to the presence of key players, favorable funding assistance, and increased patient awareness

The increase in the prevalence of congestive heart failure (CHF), the rising aging population leading to increased risk of disease, and growing research and development for better treatment approaches are the key factors augmenting the growth. In 2020, around 64.34 million people worldwide were suffering from heart failure. In addition, its estimated prevalence rate is high in patients with diseases such as diabetes and hypertension.

Increasing research and development for better treatment options is a major factor behind the presence of multiple products in the pipeline. Novo Nordisk’s Semaglutide, Zensun’s Neucardin, Bayer’s vericiguat, and AstraZeneca’s AZD4831 are among the prominent drug candidates. Moreover, approval of an extended label for sodium-glucose co-transporter 2 (SGLT2) inhibitors for CHF is expected to fuel market growth. For instance, in February 2022, Jardiance (empagliflozin) and in May 2020, Farxiga (dapagliflozin) received label expansion for the treatment of CHF.

Key players such as AstraZeneca; Bristol-Myers Squibb Company; Amgen Inc.; and Boehringer Ingelheim are strategically engaged in geographical expansions, regulatory approvals, collaborations, and partnerships through mergers and acquisitions in emerging and economically favorable regions. For instance, in February 2021, AstraZeneca announced the approval of Forxiga (dapagliflozin) in China, indicated for CHF with or without type-2 diabetes. Before China, the drug was already approved in the U.S., Europe, and Japan for the same indication.

COVID-19 impacted the demand and supply of drugs, and patients faced difficulty in healthcare access, resulting in a decline in product demand amid the pandemic. Due to imposed restrictions, research and development saw a setback in clinical trial proceedings. However, after the pandemic, the industry regained its pace.

Report Scope of the Congestive Heart Failure Drugs Market

Report Coverage


Market Size

USD 20.43 Billion by 2030

Growth Rate

CAGR of 15.9% from 2022 to 2030

Largest Market

North America

Fastest Growing Market

Asia Pacific

Base Year


Forecast Period

2022 to 2030

Segments Covered

 Drug class, distribution channel and Region,

Companies Mentioned

 Bayer AG; Novartis AG; Merck & Co., Inc.; AstraZeneca; Bristol-Myers Squibb Company; Amgen Inc.; Boehringer Ingelheim International GmbH; Pfizer, Inc.; Johnson & Johnson Services, Inc.; Otsuka Pharmaceutical Co., Ltd.; Eli Lilly and Company; Novo Nordisk A/S

Ask here for more customization study@

Drug Class Insights

The angiotensin-converting enzyme (ACE) inhibitors segment dominated the market in 2021 with a revenue share of over 31.0%. This can be due to its effectiveness as an individual treatment or approved combination therapeutic options in the market. Moreover, it is the first choice of treatment for CHF patients. It includes drugs such as Vasotec, Epaned (enalapril), Zestril, Qbrelis, Prinivil (lisinopril), and captopril. Inhibitors block the production of Angiotensin-2, and release arterial pressure, resulting in increased cardiac output without affecting heart rate. This is the most targeted mechanism of action to control heart failure.

Furthermore, approval of an extended label for sodium-glucose co-transporter 2 (SGLT2) inhibitors for CHF is anticipated to propel the segment growth. For instance, in May 2020, Farxiga (dapagliflozin) and in February 2022, Jardiance (empagliflozin) received label expansion for the treatment of CHF. These SGLT2 inhibitor drugs clinically demonstrated significant cardioprotective benefits and a 35% reduction in hospitalization. The drug class has also demonstrated clinical significance in controlling CHF in patients without diabetes.

Distribution Channel Insights 

The hospital pharmacies held the largest share of over 56.0% in 2021. The retail pharmacies segment is anticipated to witness the highest growth over the forecast period. Retail pharmacies are at ease with most medications, especially in the homecare setting as CHF disease management takes long support of medications. Additionally, CHF drugs are prescription medicines. All these factors favor the growth of the segment.

The online pharmacies segment is expected to expand at a CAGR of 13.6% during the forecast period. Online pharmacy platform encourages the comfort of buying. In addition, in developing countries such as India, companies such as Netmeds Marketplace Ltd. and Tata 1mg promote online medicines buying. However, online buying of prescription drugs is unfavorable to many individuals, which is expected to slow down online pharmacy growth. 

Regional Insights 

North America held the largest share of over 36.0% in 2021. This can be attributed to the high disease burden, rise in patient awareness, increased healthcare expenditure, and presence of major players in the region. Furthermore, rising approval of new products is expected to fuel the industry growth over the forecast period. 

In the European region, Italy was the least affected, and Germany had the highest CHF prevalence in 2021. The Asia Pacific region is expected to register the highest CAGR of 15.7% over the forecast period. This growth is due to the substantial presence of global companies in this region and the high CHF prevalence in countries such as China, Japan, and Australia. For instance, in 2020, in Australia, the estimated prevalence rate of CHF ranged between 1.2% and 5.3%, majorly due to the rising incidences of diabetes and obesity in the country.

Some of the prominent players in the Congestive Heart Failure Drugs Market include:

  • Bayer AG
  • Novartis AG
  • Merck & Co., Inc.
  • AstraZeneca
  • Bristol-Myers Squibb Company
  • Amgen Inc.
  • Boehringer Ingelheim International GmbH
  • Pfizer, Inc.
  • Johnson & Johnson Services, Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Eli Lilly and Company
  • Novo Nordisk A/S 

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Congestive Heart Failure Drugs market

  • Drug Class
    • ACE Inhibitors
    • Angiotensin 2 Receptor Blockers
    • Beta Blockers
    • Diuretics
    • Aldosterone Antagonists
    • Inotropes
    • Others
  • Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Full Report is Ready | For Purchase Inquiry@

You can place an order or ask any questions, please feel free to| +1 9197 992 333






Back to news